Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 醫學系
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/520002
Title: Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism
Authors: TUNG-HUNG SU 
HUNG-CHIH YANG 
Tseng T.-C
Chou S.-W
CHIN-HSIEN LIN 
CHEN-HUA LIU 
CHUN-JEN LIU 
CHI-LING CHEN 
JIA-HORNG KAO 
Issue Date: 2019
Publisher: John Wiley and Sons Inc.
Journal Volume: 34
Journal Issue: 12
Start page/Pages: 1882-1890
Source: Movement Disorders
Abstract: 
Background: The risk of parkinsonism after antiviral treatment against chronic hepatitis C (CHC) is unclear. Objectives: To investigate the association between CHC and parkinsonism and the efficacy of antiviral therapy. Methods: Using the National Health Insurance Research Database of Taiwan from 2004 to 2012, patients with and without CHC, patients receiving pegylated interferon-based antiviral therapy, and those without such therapy were matched by age, gender, and comorbidities by propensity scores and followed for new diagnoses of parkinsonism and Parkinson's disease (PD). Multivariable Cox proportional hazards regression analyses were performed. Results: Overall, 49,342 patients with CHC were matched with 49,342 non-CHC patients. After adjustment for confounding factors, there was a significantly increased risk (31%) of parkinsonism (hazard ratio [HR] 1.306; 95% confidence interval [CI], 1.208–1.412) in those with CHC and the risk of parkinsonism requiring anti-Parkinson medication (HR 1.323; 95% CI, 1.214–1.441). Furthermore, 23,647 untreated CHC patients were matched with 23,647 patients receiving antiviral therapy. Patients receiving antiviral therapy had a significantly lower risk of developing parkinsonism (38%; HR 0.618; 95% CI, 0.498–0.765) and a reduced risk of parkinsonism requiring anti-Parkinson medication (HR 0.651; 95% CI, 0.515–0.823). In sensitivity analyses, antiviral therapy significantly reduced the risk of parkinsonism and PD after adjustment for detection, selection, disease latency biases, and competing mortality. Our results suggest successful antiviral therapy associates with a reduced risk of hepatitis C virus–related parkinsonism compared with those with treatment failure. Conclusions: CHC infection is associated with an increased risk of parkinsonism or PD. Antiviral therapy against CHC is associated with a reduced risk of parkinsonism or PD. ? 2019 International Parkinson and Movement Disorder Society. ? 2019 International Parkinson and Movement Disorder Society
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072164517&doi=10.1002%2fmds.27848&partnerID=40&md5=424aec305e0accf5107af2f2747e6248
https://scholars.lib.ntu.edu.tw/handle/123456789/520002
ISSN: 0885-3185
DOI: 10.1002/mds.27848
SDG/Keyword: antiparkinson agent; antivirus agent; liver protective agent; peginterferon alpha2a plus ribavirin; peginterferon alpha2b plus ribavirin; alpha interferon; antivirus agent; macrogol; peginterferon alpha2a; recombinant protein; adult; antiviral therapy; Article; chronic hepatitis C; cohort analysis; comorbidity; controlled study; female; follow up; human; incidence; major clinical study; male; middle aged; parkinsonism; population research; priority journal; risk reduction; aged; chronic hepatitis C; complication; parkinsonism; risk; treatment outcome; Adult; Aged; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Parkinsonian Disorders; Polyethylene Glycols; Recombinant Proteins; Risk; Treatment Outcome
[SDGs]SDG3
Appears in Collections:醫學系

Show full item record

SCOPUSTM   
Citations

12
checked on May 23, 2023

WEB OF SCIENCETM
Citations

11
checked on May 22, 2023

Page view(s)

23
checked on May 29, 2023

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback